US approves first drug for vitreomacular adhesion, ThromboGenics' Jetrea
This article was originally published in Scrip
Executive Summary
The US FDA has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA), a progressive sight-threatening condition. Jetrea is the first pharmacological agent to be approved for this indication.